TABLE 5.
Significant factors affecting the admission duration (days)
| Univariate | Multivariate | VIF | |||
| β coefficient (95% CI) | p-value | β coefficient (95% CI) | p-value | ||
| Among all COVID-19 patients# | |||||
| Asthma | 0.947 (−0.693–2.587) | 0.258 | −0.342 (−1.993–1.309) | 0.685 | |
| Among asthma patients¶ | |||||
| ICS alone | |||||
| Past year | −1.385 (−5.306–2.537) | 0.487 | −1.083 (−6.096–3.929) | 0.670 | 1.630 |
| Past 2 months | −2.805 (−6.869–1.260) | 0.175 | −3.579 (−9.083–1.925) | 0.201 | 1.822 |
| ICS–LABA | |||||
| Past year | 0.611 (−3.094–4.316) | 0.746 | −0.794 (−5.220–3.631) | 0.724 | 1.425 |
| Past 2 months | 0.055 (−3.707–3.818) | 0.977 | −1.994 (−6.675–2.688) | 0.402 | 1.551 |
| Oral LABA | |||||
| Past year | −3.899 (−7.636–−0.162) | 0.041* | −3.503 (−7.703–0.696) | 0.102 | 1.238 |
| Past 2 months | −4.248 (−8.070–−0.428) | 0.030* | −3.744 (−8.214–0.726) | 0.100 | 1.341 |
| Patch LABA | |||||
| Past year | 0.520 (−4.095–5.135) | 0.825 | 4.516 (−1.292–10.324) | 0.127 | 1.583 |
| Past 2 months | −0.948 (−5.804–3.908) | 0.701 | 3.302 (−3.208–9.811) | 0.318 | 1.799 |
| LTRA | |||||
| Past year | −0.273 (−4.354–3.809) | 0.895 | 0.662 (−3.952–5.277) | 0.777 | 1.278 |
| Past 2 months | −1.812 (−5.626–2.002) | 0.350 | −0.620 (−5.184–3.944) | 0.789 | 1.428 |
| Inhaled SABA | |||||
| Past year | −0.573 (−4.286–3.141) | 0.762 | 1.076 (−3.748–5.900) | 0.661 | 1.686 |
| Past 2 months | 0.100 (−3.697–3.896) | 0.959 | 3.915 (−1.347–9.177) | 0.144 | 1.924 |
| Oral SABA | |||||
| Past year | 4.088 (−1.119–9.295) | 0.123 | 5.734 (0.014–11.453) | 0.049* | 1.193 |
| Past 2 months | 3.149 (−2.225–8.523) | 0.249 | 4.893 (−1.210–10.997) | 0.115 | 1.284 |
| Xanthine | |||||
| Past year | 1.036 (−2.569–4.641) | 0.572 | −0.129 (−4.095–3.836) | 0.949 | 1.208 |
| Past 2 months | 0.682 (−2.937–4.300) | 0.711 | −0.225 (−4.327–3.878) | 0.914 | 1.287 |
| Inhaled LAMA | |||||
| Past year | 0.450 (−5.210–6.111) | 0.876 | −3.046 (−10.192–4.099) | 0.402 | 1.593 |
| Past 2 months | 0.450 (−5.210–6.111) | 0.876 | −2.431 (−9.623–4.760) | 0.506 | 1.617 |
| Severity of asthma (reference step 1) | |||||
| Step 2 | 5.044 (−0.301–10.390) | 0.064 | 4.565 (−1.127–10.258) | 0.115 | 1.668 |
| Step 3 | 4.000 (−2.470–10.470) | 0.224 | 2.739 (−3.998–9.475) | 0.424 | 1.397 |
| Step 4 | 1.238 (−3.308–5.783) | 0.592 | 0.976 (−3.802–5.753) | 0.688 | 1.759 |
| Step 5 | 19.583 (6.011–33.155) | 0.005* | 18.414 (4.031–32.796) | 0.012* | 1.171 |
VIF: variance inflation factor; COVID-19: coronavirus disease 2019; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LTRA: leukotriene receptor antagonist; SABA: short-acting β2-agonist; LAMA: long-acting muscarinic antagonist. #: adjusted for age, sex and underlying disease; ¶: adjusted for age, sex, underlying disease and asthma medications/severity. *: p<0.05.